Long term outcome of Aldosteronism after target treatments
Open Access
- 2 September 2016
- journal article
- Published by Springer Science and Business Media LLC in Scientific Reports
- Vol. 6 (1), 32103
- https://doi.org/10.1038/srep32103
Abstract
There exists a great knowledge gap in terms of long-term effects of various surgical and pharmacological treatments on outcomes among primary aldosteronism (PA) patients. Using a validated algorithm, we extracted longitudinal data for all PA patients diagnosed in 1997–2010 and treated in the Taiwan National Health Insurance. We identified 3362 PA patients for whom the mean length of follow-up was 5.75 years. PA has higher major cardiovascular events (MACE) than essential hypertension (23.3% vs 19.3%, p = 0.015). Results from the Cox model suggest a strong effect of adrenalectomy on lowering mortality (HR = 0.23 with residual hypertension and 0.21 with resolved hypertension). While the need for mineralocorticoid receptor antagonist (MRA) after diagnosis suggests that a defined daily dose (DDD) of MRA between 12.5 and 50 mg may alleviate risk of death in a U-shape pattern. A specificity test identified patients who has aldosterone producing adenoma (HR = 0.50, p = 0.005) also confirmed adrenalectomy attenuated all-cause mortality. Adrenalectomy decreases long-term all-cause mortality independently from PA cure from hypertension. Prescription corresponding to a DDD between 12.5 and 50 mg may decrease mortality for patients needing MRA. It calls for more attention on early diagnosis, early treatment and prescription of appropriate dosage of MRA for PA patients.This publication has 41 references indexed in Scilit:
- Diagnosis and management of primary aldosteronism: An updated reviewAnnals of Medicine, 2013
- Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetesBMJ, 2010
- Mineralocorticoid Antagonists Treatment Versus Surgery in Primary AldosteronismHormone and Metabolic Research, 2010
- Association of Kidney Function With Residual Hypertension After Treatment of Aldosterone-Producing AdenomaAmerican Journal of Kidney Diseases, 2009
- Vascular Remodeling and Duration of Hypertension Predict Outcome of Adrenalectomy in Primary Aldosteronism PatientsHypertension, 2008
- Estimation of propensity scores using generalized additive modelsStatistics in Medicine, 2008
- Long-Term Cardiac Effects of Adrenalectomy or Mineralocorticoid Antagonists in Patients With Primary AldosteronismHypertension, 2007
- Complementary and Incremental Mortality Risk Prediction by Cortisol and Aldosterone in Chronic Heart FailureCirculation, 2007
- Evidence for an increased rate of cardiovascular events in patients with primary aldosteronismJournal of the American College of Cardiology, 2005
- The Role of Insurance Claims Databases in Drug Therapy Outcomes ResearchPharmacoEconomics, 1993